Tumour escape mechanisms and their therapeutic implications in combination tumour therapy (Q37729243)

22 August 2017

1 reference

title

Tumour escape mechanisms and their therapeutic implications in combination tumour therapy (English)

1 reference

22 August 2017

Sujit K Bhutia

1

1 reference

22 August 2017

Sanjaya K Mallick

series ordinal

2

1 reference

22 August 2017

Tapas K Maiti

series ordinal

3

1 reference

22 August 2017

publication date

8 April 2010

1 reference

Cell Biology International

22 August 2017

published in

1 reference

22 August 2017

volume

34

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

553-563

1 reference

Inflammation and cancer: how hot is the link?

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Nitric oxide and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Costimulation of T cells for tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon c

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Epigenetics in cancer: targeting chromatin modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Immune modulation by ionizing radiation and its implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

21 January 2018

DC-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Tissue homeostasis and the control of the neoplastic phenotype in epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Enhancing efficacy of therapeutic vaccinations by combination with other modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Autophagy in cancer: good, bad, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Combined antiangiogenic and immune therapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Epigenetic changes in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Death and anti-death: tumour resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Search for unknown tumor‐antagonizing genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Histone modifications as markers of cancer prognosis: a cellular view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Escape from immune- and nonimmune-mediated tumor surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Inhibitory costimulation and anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

IDO expression by dendritic cells: tolerance and tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Cancer as an evolutionary and ecological process

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Colonic Tumor CEA, CSAp and MUC-1 Expression following Radioimmunotherapy or Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Control of cancers by combining antiangiogenesis and cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Synergy between tumor immunotherapy and antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

VEGF as a mediator of tumor-associated immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Vaccines targeting tumour angiogenesis--a novel strategy for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Chronic inflammation: a common and important factor in the pathogenesis of neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

HLA class I antigen abnormalities and immune escape by malignant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Apoptosis, anoikis and their relevance to the pathobiology of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Synergistic antitumor activity of immune strategies combined with radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Suppression of lymphoma and epithelial malignancies effected by interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Tumor stress, cell death and the ensuing immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Inhibition of angiogenesis by interleukin 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic m

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Cancer despite immunosurveillance: immunoselection and immunosubversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCBI20090206

21 January 2018

Identifiers

DOI

10.1042/CBI20090206

1 reference

22 August 2017

1 reference